RenovoRx (RNXT, Financial) continues to earn confidence from the financial community as HC Wainwright & Co. reaffirmed its "Buy" rating for the company. Analyst Swayampakula Ramakanth maintained the price target at $3.00 USD, signifying a stable outlook for this biotech firm.
This confirmation, dated May 19, 2025, reflects HC Wainwright & Co.'s consistent expectations for RenovoRx (RNXT, Financial), as both the prior and current price targets remain unchanged. The decision to maintain the price target aligns with the previous guidance, signaling ongoing support and confidence in RenovoRx's (RNXT) market strategy and potential growth.
Investors should note that the reaffirmation of both the rating and price target demonstrates a steadiness in analyst expectations, which may reassure stakeholders about the company's future trajectory. The consistent advice underscores the belief in RenovoRx's (RNXT, Financial) capabilities to meet the outlined objectives within the upcoming periods.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for RenovoRx Inc (RNXT, Financial) is $6.00 with a high estimate of $11.00 and a low estimate of $3.00. The average target implies an upside of 408.47% from the current price of $1.18. More detailed estimate data can be found on the RenovoRx Inc (RNXT) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, RenovoRx Inc's (RNXT, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
